2022
P‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects
Bhardwaj R, Collins J, Stringfellow J, Madonia J, Anderson M, Finley J, Stock D, Coric V, Croop R, Bertz R. P‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects. Clinical Pharmacology In Drug Development 2022, 11: 889-897. PMID: 35304977, PMCID: PMC9311059, DOI: 10.1002/cpdd.1088.Peer-Reviewed Original ResearchConceptsBreast cancer resistance protein transporterPlasma concentration-time curveSingle oral doseGeometric mean ratiosConcentration-time curveP-glycoproteinOral doseHealthy subjectsSmall-molecule calcitonin gene-related peptide receptor antagonistCalcitonin gene-related peptide receptor antagonistStrong P-glycoprotein inhibitorBreast cancer resistance protein (BCRP) inhibitionPeptide receptor antagonistTime 0Mean ratioP-glycoprotein inhibitorsP-glycoprotein transporterConcomitant administrationCrossover studyReceptor antagonistPreventive treatmentCyclosporineCoadministrationTransporter inhibitionPharmacokinetics
2021
A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults
Croop R, Ivans A, Anderson M, Stringfellow J, Bertz R, Hanna M, Healy F, Stock D, Coric V, Lipton R. A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults. Cephalalgia Reports 2021, 4: 25158163211007922. DOI: 10.1177/25158163211007922.Peer-Reviewed Original ResearchPharmacokinetic interactionsSubcutaneous sumatriptanHemodynamic effectsBlood pressureConcomitant administrationDay 1Healthy adultsInjection of sumatriptanPlacebo-controlled studyMean arterial pressureDiastolic blood pressureInjection site reactionsSystolic blood pressureTime-weighted averageAdverse eventsArterial pressureSite reactionsConcomitant useSumatriptanDay 2Day 5Dosed subjectsPlaceboSignificant differencesPhase 1